drugset / Trial / NCT01169519

Sildenafil in Single Ventricle Patients

NCT01169519

Phase 1 Completed 21 enrolled Duke University
NaSingle-groupOpen-labelTreatment

Summary

Patients with single ventricle anatomy undergo staged surgical palliation. The result is an "in series" circulation with pulmonary blood flow and cardiac output directly related to pulmonary vascular resistance. While surgical outcomes have improved, the physiology of the single ventricle palliation results in continued long term attrition. Elevated pulmonary vascular resistance and impaired systemic ventricular function are important risk factors for failure of single ventricle palliation. Sildenafil is a pulmonary vasodilator and has been shown to improve cardiac contractility in the pressure overloaded right ventricle. The investigators will assess the safety, pharmacokinetics and hemodynamic efficacy of sildenafil in single ventricle patients following stage II and III surgical palliation.

Timeline

Start
2011-04
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sildenafil Unknown 0.125 mg/kg Intravenous
Comparator Sildenafil Unknown 0.25 mg/kg Intravenous
Comparator Sildenafil Unknown 0.35 mg/kg Intravenous
Comparator Sildenafil Unknown 0.45 mg/kg Intravenous

Indications